Details of the Drug

General Information of Drug (ID: DMIYG7Z)

• Drug Name: Donepezil
• Synonyms: Donepezil (transdermal patch, Alzheimer's disease)

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Alzheimer disease	8A20	Approved	[2]

• Therapeutic Class: Neurology Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 379.5
  Logarithm of the Partition Coefficient (xlogp); 4.3
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 11.754 mcg/L [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
  Bioavailability: The bioavailability of drug is 90% [3]
  Clearance: The clearance of drug is 0.13 C 0.19 L/h/kg [5]
  Elimination: 57% of drug was eliminated in the urine, and 5% was eliminated in the feces [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 70 hours [7]
  Metabolism: The drug is metabolized via the CYP3A4 and CYP2D6 in the liver [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3764 micromolar/kg/day [8]
  Vd: The volume of distribution (Vd) of drug is 11.8 +/- 1.7 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.0029 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Dizziness	Not Available	BCHE	OTOH3WQ9	[9]

• Chemical Identifiers:
  Formula: C24H29NO3
  IUPAC Name: 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
  Canonical SMILES: COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC
  InChI: InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
  InChIKey: ADEBPBSSDYVVLD-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3152
  ChEBI ID: CHEBI:53289
  CAS Number: 120014-06-4
  DrugBank ID: DB00843
  TTD ID: D0NS6H
  VARIDT ID: DR00817
  INTEDE ID: DR0530
  ACDINA ID: D00211
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Modulator	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[12]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Drug Response	[9]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[13]

Molecular Expression Atlas of This Drug

• The Studied Disease: Advanced cancer
• ICD Disease Classification: 2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Acetylcholinesterase (AChE)	DTT	ACHE	6.39E-02	-1.07	-1.15
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.35E-01	2.78E-02	2.09E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Donepezil

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Rivastigmine	DMG629M	Moderate	Additive cholinergic effects by the combination of Donepezil and Rivastigmine.	Alzheimer disease [8A20]	[14]

Coadministration of a Drug Treating the Disease Different from Donepezil (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Moderate	Additive cholinergic effects by the combination of Donepezil and Bethanechol.	Abnormal micturition [MF50]	[14]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Donepezil caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[14]
Midostaurin	DMI6E0R	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Midostaurin.	Acute myeloid leukaemia [2A60]	[15]
Idarubicin	DMM0XGL	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Idarubicin.	Acute myeloid leukaemia [2A60]	[15]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Donepezil caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[14]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Gilteritinib.	Acute myeloid leukaemia [2A60]	[15]
Oliceridine	DM6MDCF	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Oliceridine.	Acute pain [MG31]	[15]
Mepyramine	DMB4SFH	Moderate	Antagonize the effect of Donepezil when combined with Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Phenyltoloxamine	DMKAEQW	Moderate	Antagonize the effect of Donepezil when combined with Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Metronidazole	DMTIVEN	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Metronidazole.	Amoebiasis [1A36]	[15]
Bedaquiline	DM3906J	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[15]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Donepezil caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[14]
Posaconazole	DMUL5EW	Minor	Decreased metabolism of Donepezil caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[14]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Terbutaline.	Asthma [CA23]	[15]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Salbutamol.	Asthma [CA23]	[17]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Donepezil and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[18]
Desipramine	DMT2FDC	Moderate	Antagonize the effect of Donepezil when combined with Desipramine.	Attention deficit hyperactivity disorder [6A05]	[19]
Ofloxacin	DM0VQN3	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Dalfopristin	DM4LTKV	Minor	Decreased metabolism of Donepezil caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Clarithromycin	DM4M1SG	Minor	Decreased metabolism of Donepezil caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Sparfloxacin	DMB4HCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Gemifloxacin	DMHT34O	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Levofloxacin	DMS60RB	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Donepezil caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Telithromycin	DMZ4P3A	Minor	Decreased metabolism of Donepezil caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Retigabine	DMGNYIH	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Retigabine.	Behcet disease [4A62]	[15]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Donepezil caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[14]
Eribulin	DM1DX4Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Eribulin.	Breast cancer [2C60-2C6Y]	[15]
Lapatinib	DM3BH1Y	Minor	Decreased metabolism of Donepezil caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[14]
Tucatinib	DMBESUA	Minor	Decreased metabolism of Donepezil caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[14]
Palbociclib	DMD7L94	Minor	Decreased metabolism of Donepezil caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[14]
Bosutinib	DMTI8YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Bosutinib.	Breast cancer [2C60-2C6Y]	[15]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[15]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[15]
Halothane	DM80OZ5	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Halothane.	Corneal disease [9A76-9A78]	[15]
Sevoflurane	DMC9O43	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Sevoflurane.	Corneal disease [9A76-9A78]	[15]
Probucol	DMVZQ2M	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Probucol.	Coronary atherosclerosis [BA80]	[15]
Clofazimine	DMEBOFW	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Clofazimine.	Crohn disease [DD70]	[15]
Pasireotide	DMHM7JS	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Pasireotide.	Cushing syndrome [5A70]	[15]
Osilodrostat	DMIJC9X	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Osilodrostat.	Cushing syndrome [5A70]	[15]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Donepezil caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[14]
Ivacaftor	DMZC1HS	Minor	Decreased metabolism of Donepezil caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[14]
MK-8228	DMOB58Q	Minor	Decreased metabolism of Donepezil caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[14]
Sertraline	DM0FB1J	Minor	Decreased metabolism of Donepezil caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[14]
Cyclobenzaprine	DM1YBRM	Moderate	Antagonize the effect of Donepezil when combined with Cyclobenzaprine.	Depression [6A70-6A7Z]	[19]
Nefazodone	DM4ZS8M	Minor	Decreased metabolism of Donepezil caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[14]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Donepezil when combined with OPC-34712.	Depression [6A70-6A7Z]	[19]
Clomipramine	DMINRKW	Moderate	Antagonize the effect of Donepezil when combined with Clomipramine.	Depression [6A70-6A7Z]	[19]
Doxepin	DMPI98T	Moderate	Antagonize the effect of Donepezil when combined with Doxepin.	Depression [6A70-6A7Z]	[19]
Maprotiline	DMPWB7T	Moderate	Antagonize the effect of Donepezil when combined with Maprotiline.	Depression [6A70-6A7Z]	[19]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Donepezil when combined with Mepenzolate.	Digestive system disease [DE2Z]	[19]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[15]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Deutetrabenazine.	Dystonic disorder [8A02]	[15]
Ingrezza	DMVPLNC	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Ingrezza.	Dystonic disorder [8A02]	[15]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Donepezil caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Donepezil caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Donepezil caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Donepezil caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Donepezil when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[19]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Donepezil caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[14]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Donepezil caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[14]
Tolterodine	DMSHPW8	Moderate	Antagonize the effect of Donepezil when combined with Tolterodine.	Functional bladder disorder [GC50]	[19]
Terbinafine	DMI6HUW	Minor	Decreased metabolism of Donepezil caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Miconazole	DMPMYE8	Minor	Decreased metabolism of Donepezil caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Ketoconazole	DMPZI3Q	Minor	Decreased metabolism of Donepezil caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Sunitinib	DMCBJSR	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Cyclopentolate	DMA8LM5	Moderate	Antagonize the effect of Donepezil when combined with Cyclopentolate.	General examination [QA00]	[20]
Boceprevir	DMBSHMF	Minor	Decreased metabolism of Donepezil caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
Telaprevir	DMMRV29	Minor	Decreased metabolism of Donepezil caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
Isoniazid	DM5JVS3	Minor	Decreased metabolism of Donepezil caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[14]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Donepezil caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[21]
Fosamprenavir	DM4W9B3	Minor	Decreased metabolism of Donepezil caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Fostemsavir	DM50ILT	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Cobicistat	DM6L4H2	Minor	Decreased metabolism of Donepezil caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Donepezil caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Darunavir	DMN3GCH	Minor	Decreased metabolism of Donepezil caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
BMS-201038	DMQTAGO	Minor	Decreased metabolism of Donepezil caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[14]
Cinacalcet	DMCX0K3	Minor	Decreased metabolism of Donepezil caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[14]
Conivaptan	DM1V329	Minor	Decreased metabolism of Donepezil caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[14]
Givosiran	DM5PFIJ	Minor	Decreased metabolism of Donepezil caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[14]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Donepezil when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[19]
Berotralstat	DMWA2DZ	Minor	Decreased metabolism of Donepezil caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[14]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Donepezil caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[14]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Donepezil when combined with ITI-007.	Insomnia [7A00-7A0Z]	[19]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Donepezil and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[23]
Physostigmine	DM2N0TO	Moderate	Additive cholinergic effects by the combination of Donepezil and Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[14]
Glycerol phenylbutyrate	DMDGRQO	Minor	Decreased metabolism of Donepezil caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[14]
Crizotinib	DM4F29C	Minor	Decreased metabolism of Donepezil caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[14]
Ceritinib	DMB920Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Ceritinib.	Lung cancer [2C25]	[15]
Dacomitinib	DMOH8VY	Minor	Decreased metabolism of Donepezil caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[14]
Osimertinib	DMRJLAT	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Osimertinib.	Lung cancer [2C25]	[15]
Selpercatinib	DMZR15V	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Selpercatinib.	Lung cancer [2C25]	[15]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Donepezil caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[17]
Halofantrine	DMOMK1V	Minor	Decreased metabolism of Donepezil caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[14]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Hydroxychloroquine.	Malaria [1F40-1F45]	[15]
Primaquine	DMWQ16I	Minor	Decreased metabolism of Donepezil caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[14]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[15]
Idelalisib	DM602WT	Minor	Decreased metabolism of Donepezil caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[14]
IPI-145	DMWA24P	Minor	Decreased metabolism of Donepezil caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[14]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[15]
Vemurafenib	DM62UG5	Minor	Decreased metabolism of Donepezil caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[14]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Donepezil caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[18]
Danazol	DML8KTN	Minor	Decreased metabolism of Donepezil caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[14]
Exjade	DMHPRWG	Moderate	Increased metabolism of Donepezil caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[14]
Panobinostat	DM58WKG	Minor	Decreased metabolism of Donepezil caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[14]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Thalidomide.	Multiple myeloma [2A83]	[17]
Siponimod	DM2R86O	Major	Increased risk of bradycardia by the combination of Donepezil and Siponimod.	Multiple sclerosis [8A40]	[17]
Fingolimod	DM5JVAN	Moderate	Increased risk of bradycardia by the combination of Donepezil and Fingolimod.	Multiple sclerosis [8A40]	[24]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Donepezil and Ozanimod.	Multiple sclerosis [8A40]	[25]
Neostigmine	DM6T2J3	Moderate	Additive cholinergic effects by the combination of Donepezil and Neostigmine.	Myasthenia gravis [8C6Y]	[14]
Edrophonium	DMCRQHB	Moderate	Additive cholinergic effects by the combination of Donepezil and Edrophonium.	Myasthenia gravis [8C6Y]	[14]
Ambenonium	DMOP0BL	Moderate	Additive cholinergic effects by the combination of Donepezil and Ambenonium.	Myasthenia gravis [8C6Y]	[14]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Romidepsin.	Mycosis fungoides [2B01]	[15]
Fedratinib	DM4ZBK6	Minor	Decreased metabolism of Donepezil caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[14]
Nilotinib	DM7HXWT	Minor	Decreased metabolism of Donepezil caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[14]
Dasatinib	DMJV2EK	Minor	Decreased metabolism of Donepezil caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[14]
Phenindamine	DMDTC7R	Moderate	Antagonize the effect of Donepezil when combined with Phenindamine.	Nasopharyngitis [CA00]	[19]
Dimenhydrinate	DM264B3	Moderate	Antagonize the effect of Donepezil when combined with Dimenhydrinate.	Nausea/vomiting [MD90]	[19]
Promethazine	DM6I5GR	Moderate	Antagonize the effect of Donepezil when combined with Promethazine.	Nausea/vomiting [MD90]	[19]
Rolapitant	DM8XP26	Minor	Decreased metabolism of Donepezil caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[14]
Cyclizine	DM9G7BS	Moderate	Antagonize the effect of Donepezil when combined with Cyclizine.	Nausea/vomiting [MD90]	[19]
Granisetron	DMIUW25	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Granisetron.	Nausea/vomiting [MD90]	[15]
Ondansetron	DMOTQ1I	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Ondansetron.	Nausea/vomiting [MD90]	[15]
Bupropion	DM5PCS7	Major	Decreased metabolism of Donepezil caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[15]
Entrectinib	DMMPTLH	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Entrectinib.	Non-small cell lung cancer [2C25]	[15]
Lorcaserin	DMG6OYJ	Minor	Decreased metabolism of Donepezil caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[14]
Dexfenfluramine	DMJ7YDS	Minor	Decreased metabolism of Donepezil caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[14]
Levomethadyl Acetate	DM06HG5	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Levomethadyl Acetate.	Opioid use disorder [6C43]	[17]
Lofexidine	DM1WXA6	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Lofexidine.	Opioid use disorder [6C43]	[15]
Rucaparib	DM9PVX8	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Rucaparib.	Ovarian cancer [2C73]	[15]
Flavoxate	DMKV4NL	Moderate	Antagonize the effect of Donepezil when combined with Flavoxate.	Pain [MG30-MG3Z]	[19]
Buprenorphine	DMPRI8G	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Buprenorphine.	Pain [MG30-MG3Z]	[15]
Triclabendazole	DMPWGBR	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Triclabendazole.	Parasitic worm infestation [1F90]	[15]
Pimavanserin	DMR7IVC	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Pimavanserin.	Parkinsonism [8A00]	[15]
Orphenadrine	DMW542E	Moderate	Antagonize the effect of Donepezil when combined with Orphenadrine.	Parkinsonism [8A00]	[19]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Donepezil caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[26]
Ranitidine	DM0GUSX	Moderate	Antagonize the effect of Donepezil when combined with Ranitidine.	Peptic ulcer [DA61]	[19]
Methylscopolamine	DM5VWOB	Moderate	Antagonize the effect of Donepezil when combined with Methylscopolamine.	Peptic ulcer [DA61]	[19]
Famotidine	DMRL3AB	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Famotidine.	Peptic ulcer [DA61]	[15]
Macimorelin	DMQYJIR	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[15]
Lefamulin	DME6G97	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Lefamulin.	Pneumonia [CA40]	[15]
Lonafarnib	DMGM2Z6	Minor	Decreased metabolism of Donepezil caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[14]
Degarelix	DM3O8QY	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Degarelix.	Prostate cancer [2C82]	[15]
ABIRATERONE	DM8V75C	Minor	Decreased metabolism of Donepezil caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[14]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Donepezil caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[14]
Relugolix	DMK7IWL	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Relugolix.	Prostate cancer [2C82]	[15]
Bicalutamide	DMZMSPF	Minor	Decreased metabolism of Donepezil caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[14]
Levomepromazine	DMIKFEL	Moderate	Antagonize the effect of Donepezil when combined with Levomepromazine.	Psychotic disorder [6A20-6A25]	[19]
Everolimus	DM8X2EH	Minor	Decreased metabolism of Donepezil caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[14]
Gatifloxacin	DMSL679	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[15]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Donepezil caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[14]
Oxamniquine	DM2QDX1	Minor	Decreased metabolism of Donepezil caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[14]
Quetiapine	DM1N62C	Moderate	Antagonize the effect of Donepezil when combined with Quetiapine.	Schizophrenia [6A20]	[19]
Mesoridazine	DM2ZGAN	Moderate	Antagonize the effect of Donepezil when combined with Mesoridazine.	Schizophrenia [6A20]	[19]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Donepezil when combined with Aripiprazole.	Schizophrenia [6A20]	[19]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Iloperidone.	Schizophrenia [6A20]	[15]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Paliperidone.	Schizophrenia [6A20]	[15]
Molindone	DMAH70G	Moderate	Antagonize the effect of Donepezil when combined with Molindone.	Schizophrenia [6A20]	[19]
Thiothixene	DMDINC4	Moderate	Antagonize the effect of Donepezil when combined with Thiothixene.	Schizophrenia [6A20]	[19]
Asenapine	DMSQZE2	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Asenapine.	Schizophrenia [6A20]	[15]
Pimozide	DMW83TP	Moderate	Antagonize the effect of Donepezil when combined with Pimozide.	Schizophrenia [6A20]	[19]
Vardenafil	DMTBGW8	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Vardenafil.	Sexual dysfunction [HA00-HA01]	[15]
Voxelotor	DMCS6M5	Minor	Decreased metabolism of Donepezil caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[14]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Donepezil caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[18]
Larotrectinib	DM26CQR	Minor	Decreased metabolism of Donepezil caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[14]
Armodafinil	DMGB035	Minor	Increased metabolism of Donepezil caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[27]
LEE011	DMMX75K	Minor	Decreased metabolism of Donepezil caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Vandetanib	DMRICNP	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[15]
Triptorelin	DMTK4LS	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Doxorubicin	DMVP5YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Pitolisant	DM8RFNJ	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Pitolisant.	Somnolence [MG42]	[15]
Telavancin	DM58VQX	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[15]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Donepezil caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[28]
Cabozantinib	DMIYDT4	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Cabozantinib.	Thyroid cancer [2D10]	[15]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Donepezil caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[14]
Chlorpheniramine	DM5URA2	Moderate	Antagonize the effect of Donepezil when combined with Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[19]
Methdilazine	DMAUHQX	Moderate	Antagonize the effect of Donepezil when combined with Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[19]
Trimeprazine	DMEMV9D	Moderate	Antagonize the effect of Donepezil when combined with Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[16]
Acrivastine	DMTIGA0	Moderate	Antagonize the effect of Donepezil when combined with Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[19]
Procainamide	DMNMXR8	Moderate	Antagonize the effect of Donepezil when combined with Procainamide.	Ventricular tachyarrhythmia [BC71]	[19]
Propafenone	DMPIBJK	Minor	Decreased metabolism of Donepezil caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[14]
Flecainide	DMSQDLE	Moderate	Increased risk of ventricular arrhythmias by the combination of Donepezil and Flecainide.	Ventricular tachyarrhythmia [BC71]	[15]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Aspartame	E00402	134601	Flavoring agent
FD&C blue no. 2	E00446	2723854	Colorant
Fumaric acid	E00420	444972	Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Monoammonium glycyrrhizate	E00352	62074	Emulsifying agent; Flavoring agent
Sodium stearyl fumarate	E00545	23665634	lubricant
Sucralose	E00370	71485	Flavoring agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate	E00671	Not Available	Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid	E00029	875	Acidulant; Complexing agent; Flavoring agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Zinc sulfate monohydrate	E00358	62639	Anticaking agent; Antimicrobial preservative

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Donepezil 10 mg tablet	10 mg	Disintegrating Oral Tablet	Oral
Donepezil 5 mg tablet	5 mg	Disintegrating Oral Tablet	Oral
Donepezil 10 mg tablet	10 mg	Disintegrating Tablet	Oral
Donepezil 5 mg tablet	5 mg	Disintegrating Tablet	Oral
Donepezil 23 mg tablet	23 mg	Oral Tablet	Oral
Donepezil 10 mg tablet	10 mg	Oral Tablet	Oral
Donepezil 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Donepezil FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6599).
• [3] Fluoxetine: A case history of its discovery and preclinical development
• [4] BDDCS applied to over 900 drugs
• [5] Donepezil FDA label
• [6] Seltzer B: Donepezil: a review. Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):527-36. doi: 10.1517/17425255.1.3.527 .
• [7] Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:1-6. doi: 10.1046/j.1365-2125.1998.0460s1001.x.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [11] Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
• [12] Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. J Pharmacol Sci. 2015 Nov;129(3):188-95.
• [13] Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients. J Alzheimers Dis. 2012;30(4):745-9. doi: 10.3233/JAD-2012-112123.
• [14] Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
• [15] Canadian Pharmacists Association.
• [16] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA "The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?" J Am Geriatr Soc 52 (2004): 2082-7. [PMID: 15571547]
• [17] Cerner Multum, Inc. "Australian Product Information.".
• [18] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [19] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [20] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13. [PMID: 9434659]
• [21] Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [22] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [23] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [24] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [25] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [26] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [27] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [28] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.